1A0L | A:28-120,A:233-245; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245 | HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE |
1A2C | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA |
1A3B | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1 |
1A3E | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2 |
1A46 | H:28-120,H:233-245; H:16-27,H:121-232 | THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR |
1A4W | H:28-120,H:233-239; H:16-27,H:121-232 | CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE |
1A5G | H:28-120,H:233-245; H:16-27,H:121-232 | HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN |
1A5H | A:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242 | CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE |
1A61 | H:28-120,H:233-245; H:16-27,H:121-232 | THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR |
1A7S | A:1-12,A:108-207; A:13-107,A:208-221 | ATOMIC RESOLUTION STRUCTURE OF HBP |
1ABI | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS |
1ABJ | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS |
1AD8 | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY |
1AE5 | A:1-12,A:108-207; A:13-107,A:208-221 | HUMAN HEPARIN BINDING PROTEIN |
1AE8 | H:28-120,H:233-246; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP |
1AFE | H:28-120,H:233-246; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP |
1AHT | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION |
1AI8 | H:28-120,H:233-243; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG |
1AIX | H:28-120,H:233-243; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL |
1AU8 | A:16-27,A:121-232; A:28-120,A:233-244 | HUMAN CATHEPSIN G |
1AUT | C:28-120,C:233-243; C:16-27,C:121-232 | HUMAN ACTIVATED PROTEIN C |
1AWF | H:28-120,H:233-246; H:16-27,H:121-232 | NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT |
1AWH | B:28-120,B:233-246; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-246 | NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT |
1AY6 | H:28-120,H:233-245; H:16-27,H:121-232 | THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF |
1B0F | A:16-27,A:121-232; A:28-120,A:233-243 | CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101, 146 |
1B5G | H:28-120,H:233-245; H:16-27,H:121-232 | HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN |
1B7X | B:28-120,B:233-242; B:16-27,B:121-232 | STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
1BA8 | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES |
1BB0 | B:28-120,B:233-244; B:16-27,B:121-232 | THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES |
1BCU | H:28-120,H:233-244; H:16-27,H:121-232 | ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN |
1BDA | A:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242 | CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE) |
1BHX | F:150-247; B:16-147 | X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357 |
1BIO | A:28-122,A:233-243; A:16-27,A:123-232 | HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR |
1BML | A:574-664,A:779-790; A:562-573,A:665-778; B:562-573,B:665-778; B:574-664,B:779-790 | COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE |
1BMM | H:28-120,H:233-246; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL) AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282) |
1BMN | H:28-120,H:233-245; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090) |
1BUI | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-244 | STRUCTURE OF THE TERNARY MICROPLASMIN-STAPHYLOKINASE-MICROPLASMIN COMPLEX: A PROTEINASE-COFACTOR-SUBSTRATE COMPLEX IN ACTION |
1C1U | H:28-120,H:239-252; H:16-27,H:121-238 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1V | H:28-120,H:239-252; H:16-27,H:121-238 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1W | H:28-120,H:239-252; H:16-27,H:121-238 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C4U | 2:28-120,2:233-246; 2:16-27,2:121-232 | SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES. |
1C4V | 2:28-120,2:233-246; 2:16-27,2:121-232 | SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES. |
1C4Y | 2:28-120,2:233-245; 2:16-27,2:121-232 | SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS |
1C5L | H:28-120,H:233-245; H:16-27,H:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5M | D:16-27,D:121-232; D:28-120,D:233-250 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5N | H:28-120,H:233-245; H:16-27,H:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5O | H:28-120,H:233-245; H:16-27,H:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5W | B:28-120,B:233-245; B:16-27,B:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5X | B:28-120,B:233-245; B:16-27,B:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5Y | B:28-120,B:233-245; B:16-27,B:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5Z | B:28-120,B:233-242; B:16-27,B:121-232 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1CA8 | B:28-120,B:233-243; B:16-27,B:121-232 | THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES |
1CGH | A:16-27,A:121-232; A:28-120,A:233-244 | HUMAN CATHEPSIN G |
1CVW | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA) |
1D3D | B:49-153,B:281-292; B:37-48,B:154-280 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4 |
1D3P | B:49-153,B:281-292; B:37-48,B:154-280 | CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3 |
1D3Q | B:49-153,B:281-292; B:37-48,B:154-280 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2 |
1D3T | B:49-153,B:281-292; B:37-48,B:154-280 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1 |
1D4P | B:49-153,B:281-292; B:37-48,B:154-280 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR |
1D6W | A:28-120,A:233-243; A:16-27,A:121-232 | STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1 |
1D9I | A:28-120,A:233-244; A:16-27,A:121-232 | STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1 |
1DAN | H:16-27,H:121-232; H:28-120,H:233-246 | COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR |
1DDJ | A:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791 | CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN |
1DE7 | H:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-245 | INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX |
1DFP | A:28-122,A:233-243; B:28-122,B:233-243; A:16-27,A:123-232; B:16-27,B:123-232 | FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE |
1DIC | A:28-122,A:233-243; A:16-27,A:123-232 | STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D |
1DIT | H:28-120,H:233-246; H:16-27,H:121-232 | COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN |
1DLE | A:1-120,A:233-248; B:1-120,B:233-248; B:121-229; A:121-229 | FACTOR B SERINE PROTEASE DOMAIN |
1DM4 | B:28-120,B:233-246; B:16-27,B:121-232 | SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16) |
1DOJ | A:28-120,A:233-245; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN*RWJ-51438 COMPLEX AT 1.7 A |
1DST | A:28-122,A:233-243; A:16-27,A:123-232 | MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY |
1DSU | A:28-122,A:233-243; B:28-122,B:233-242; A:16-27,A:123-232; B:16-27,B:123-232 | HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME |
1DVA | H:16-27,H:121-232; I:16-27,I:121-232; H:28-120,H:233-246; I:28-120,I:233-246 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA |
1DWB | H:28-120,H:233-244; H:16-27,H:121-232 | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS |
1DWC | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS |
1DWD | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS |
1DWE | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS |
1DX5 | M:28-120,M:233-246; M:16-27,M:121-232; N:16-27,N:121-232; O:16-27,O:121-232; P:16-27,P:121-232; N:28-120,N:233-246; O:28-120,O:233-246; P:28-120,P:233-246 | CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX |
1E0F | E:28-120,E:233-244; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-246 | CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR |
1EAW | A:28-120,A:233-244; C:28-120,C:233-244; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE MTSP1 (MATRIPTASE)-BPTI (APROTININ) COMPLEX |
1EAX | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF MTSP1 (MATRIPTASE) |
1EB1 | H:28-120,H:233-245; H:16-27,H:121-232 | COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR |
1EJN | A:28-120,A:233-244; A:16-27,A:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX |
1ELV | A:423-436,A:534-655; A:437-532,A:656-664 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE |
1EOJ | A:28-120,A:233-243; A:16-27,A:121-232 | DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES |
1EOL | A:28-120,A:233-243; A:16-27,A:121-232 | DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES |
1EZQ | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515 |
1EZX | C:42-245 | CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX |
1F0R | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815 |
1F0S | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707 |
1F5K | U:28-120,U:233-244; U:16-27,U:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX |
1F5L | A:28-120,A:233-242; A:16-27,A:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX |
1F92 | A:28-120,A:233-244; A:16-27,A:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX |
1FAK | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT |
1FAX | A:16-27,A:121-232; A:28-120,A:233-245 | COAGULATION FACTOR XA INHIBITOR COMPLEX |
1FDP | A:28-122,A:233-242; B:28-122,B:233-240; C:28-122,C:233-240; D:28-122,D:233-240; A:17-27,A:123-232; B:22-27,B:123-232; D:22-27,D:123-232; C:22-27,C:123-232 | PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D |
1FJS | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA |
1FPC | H:28-120,H:233-243; H:16-27,H:121-232 | ACTIVE SITE MIMETIC INHIBITION OF THROMBIN |
1FPH | H:28-120,H:233-247; H:16-27,H:121-232 | THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY |
1FQ3 | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF HUMAN GRANZYME B |
1FUJ | A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-243; B:28-120,B:233-243; C:28-120,C:233-243; D:28-120,D:233-243 | PR3 (MYELOBLASTIN) |
1FV9 | A:13-118,A:235-244; A:1-12,A:119-234 | CRYSTAL STRUCTURE OF HUMAN MICROUROKINASE IN COMPLEX WITH 2-AMINO-5-HYDROXY-BENZIMIDAZOLE |
1FXY | A:16-27,A:121-232; A:28-120,A:233-246 | COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
1FY1 | A:1-12,A:108-207; A:13-107,A:208-221 | [R23S,F25E]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37) |
1FY3 | A:1-12,A:108-207; A:13-107,A:208-221 | [G175Q]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37) |
1G2L | A:16-27,A:122-237; A:28-121,A:238-250 | FACTOR XA INHIBITOR COMPLEX |
1G2M | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA INHIBITOR COMPLEX |
1G30 | B:28-120,B:233-245; B:16-27,B:121-232 | THROMBIN INHIBITOR COMPLEX |
1G32 | B:28-120,B:233-245; B:16-27,B:121-232 | THROMBIN INHIBITOR COMPLEX |
1G37 | A:28-120,A:233-243; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE |
1GHV | H:28-120,H:233-244; H:16-27,H:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GHW | H:28-120,H:233-242; H:16-27,H:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GHX | H:28-120,H:233-244; H:16-27,H:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GHY | H:28-120,H:233-244; H:16-27,H:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI7 | B:28-120,B:233-242; B:16-27,B:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI8 | B:28-120,B:233-242; B:16-27,B:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI9 | B:28-120,B:233-242; B:16-27,B:121-232 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GJ4 | H:28-120,H:233-245; H:16-27,H:121-232 | SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN |
1GJ5 | H:28-120,H:233-244; H:16-27,H:121-232 | SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN |
1GJ7 | B:28-120,B:233-243; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJ8 | B:28-120,B:233-242; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJ9 | B:28-120,B:233-243; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJA | B:28-120,B:233-242; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJB | B:28-120,B:233-243; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJC | B:28-120,B:233-243; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GJD | B:28-120,B:233-242; B:16-27,B:121-232 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GPZ | A:560-675; B:560-675; B:461-558,B:676-681; A:461-558,A:676-681; A:442-460; B:442-460 | THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R |
1GVL | A:16-27,A:121-232; A:28-120,A:233-244 | HUMAN PROKALLIKREIN 6 (HK6)/ PROZYME/ PROPROTEASE M/ PRONEUROSIN |
1H1B | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243 | CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE COMPLEXED WITH AN INHIBITOR (GW475151) |
1H4W | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURE OF HUMAN TRYPSIN IV (BRAIN TRYPSIN) |
1H8D | H:28-120,H:233-245; H:16-27,H:121-232 | X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR. |
1H8I | H:28-120,H:233-245; H:16-27,H:121-232 | X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR. |
1HAG | E:28-120,E:233-247; E:16-27,E:121-232 | THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN |
1HAH | H:28-120,H:233-246; H:16-27,H:121-232 | THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN |
1HAI | H:28-120,H:233-246; H:16-27,H:121-232 | THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN |
1HBT | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR |
1HCG | A:16-27,A:121-232; A:28-120,A:233-251 | STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION |
1HDT | H:28-120,H:233-247; H:16-27,H:121-232 | STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN |
1HFD | A:28-122,A:233-243; A:16-27,A:123-232 | HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM |
1HGT | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN |
1HLT | H:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-243 | THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN |
1HNE | E:16-27,E:121-232; E:28-120,E:233-243 | STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A PEPTIDE CHLOROMETHYL KETONE INHIBITOR AT 1.84-ANGSTROMS RESOLUTION |
1HXE | H:28-120,H:233-243; H:16-27,H:121-232 | SERINE PROTEASE |
1HXF | H:28-120,H:233-243; H:16-27,H:121-232 | HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT |
1IAU | A:16-27,A:121-232; A:28-120,A:233-244 | HUMAN GRANZYME B IN COMPLEX WITH AC-IEPD-CHO |
1IHS | H:28-120,H:233-246; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6 |
1IHT | H:28-120,H:233-246; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6 |
1IOE | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55532 |
1IQE | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55590 |
1IQF | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55165 |
1IQG | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55159 |
1IQH | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55143 |
1IQI | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55125 |
1IQJ | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55124 |
1IQK | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55113 |
1IQL | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54476 |
1IQM | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54471 |
1IQN | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55192 |
1J9C | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX |
1JBU | H:20-27,H:121-232; H:28-120,H:233-246 | COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183 |
1JMO | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX |
1JOU | B:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-245 | CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE |
1JWT | A:49-153,A:275-287; A:16-48,A:154-274 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR |
1K21 | H:28-120,H:233-243; H:16-27,H:121-232 | HUMAN THROMBIN-INHIBITOR COMPLEX |
1K22 | H:28-120,H:233-245; H:16-27,H:121-232 | HUMAN THROMBIN-INHIBITOR COMPLEX |
1KLI | H:16-27,H:121-232; H:28-120,H:233-246 | COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA |
1KLJ | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA |
1KLT | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION |
1KSN | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH FXV673 |
1KTS | B:28-120,B:233-245; B:16-27,B:121-232 | THROMBIN INHIBITOR COMPLEX |
1KTT | B:28-120,B:233-245; B:16-27,B:121-232 | THROMBIN INHIBITOR COMPLEX |
1KYE | | [entry was replaced by entry 3LIW without any CATH domain information] |
1KYN | A:16-27,A:121-232; B:316-327,B:421-532; B:328-420,B:533-544; A:28-120,A:233-243 | CATHEPSIN-G |
1L2E | A:16-27,A:121-232; A:28-120,A:233-243 | HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR |
1L4D | A:574-664,A:779-790; A:562-573,A:665-778 | CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX |
1L4Z | A:574-664,A:779-790; A:562-573,A:665-778 | X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS |
1LCY | A:6-109,A:204-210; A:110-202 | CRYSTAL STRUCTURE OF THE MITOCHONDRIAL SERINE PROTEASE HTRA2 |
1LHC | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH |
1LHD | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH |
1LHE | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH |
1LHF | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH |
1LHG | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH |
1LMW | B:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245 | LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE) |
1LO6 | A:16-27,A:121-232; A:28-120,A:233-243 | HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR AT 1.56 A RESOLUTION |
1LPG | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. |
1LPK | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. |
1LPZ | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. |
1LQD | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. |
1LTO | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN ALPHA1-TRYPTASE |
1MD7 | A:449-460,A:560-675; A:461-558,A:676-683 | MONOMERIC STRUCTURE OF THE ZYMOGEN OF COMPLEMENT PROTEASE C1R |
1MD8 | A:447-460,A:560-675; A:461-558,A:676-683 | MONOMERIC STRUCTURE OF THE ACTIVE CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R |
1MH0 | A:28-120,A:233-243; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-243 | CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN |
1MQ5 | A:16-27,A:121-232; A:28-120,A:233-243 | CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA |
1MQ6 | A:16-27,A:121-232; A:28-120,A:233-243 | CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL) METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA |
1MU6 | B:28-120,B:233-244; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378,622 |
1MU8 | B:28-120,B:233-244; B:16-27,B:121-232 | THROMBIN-HIRUGEN_L-378,650 |
1MUE | B:28-120,B:233-244; B:16-27,B:121-232 | THROMBIN-HIRUGEN-L405,426 |
1MZA | A:28-120,A:233-245; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K |
1MZD | A:28-120,A:233-245; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K |
1NFU | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747 |
1NFW | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685 |
1NFX | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944 |
1NFY | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095 |
1NM6 | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT 1.8A |
1NN6 | A:18-27,A:123-228; A:28-122,A:229-240 | HUMAN PRO-CHYMASE |
1NO9 | H:28-120,H:233-245; H:16-27,H:121-232 | DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES. |
1NRN | H:28-120,H:233-242; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NRO | H:28-120,H:233-244; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NRP | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NRQ | H:28-120,H:233-238; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NRR | H:28-120,H:233-244; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NRS | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES |
1NT1 | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR |
1NU7 | B:28-120,B:233-245; B:16-27,B:121-232; F:16-27,F:121-232; F:28-120,F:233-245 | STAPHYLOCOAGULASE-THROMBIN COMPLEX |
1NU9 | D:28-120,D:233-245; A:16-27,A:121-232; D:16-27,D:121-232; A:28-120,A:233-246 | STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX |
1NY2 | 2:28-120,2:233-245; 2:16-27,2:121-232 | HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN |
1NZQ | H:28-120,H:233-244; H:16-27,H:121-232 | D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR |
1O0D | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C-TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR |
1O2G | H:28-120,H:233-245; H:16-27,H:121-232 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3P | B:28-120,B:233-243; B:16-27,B:121-232 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O5A | B:28-120; B:16-27,B:121-243 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5B | B:28-120; B:16-27,B:121-242 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5C | B:28-120; B:16-27,B:121-243 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5D | H:16-27,H:121-232; H:28-120,H:233-246 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5E | H:16-27,H:121-230; H:28-120,H:231-255 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5F | H:16-27,H:121-230; H:28-120,H:231-255 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O5G | H:28-120,H:233-245; H:16-27,H:121-232 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1OOK | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN |
1OP8 | A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-246; B:28-120,B:233-246; C:28-120,C:233-246; D:28-120,D:233-246; E:28-120,E:233-246; F:28-120,F:233-246 | CRYSTAL STRUCTURE OF HUMAN GRANZYME A |
1OPH | B:16-27,B:121-232; B:28-120,B:233-245 | NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN |
1ORF | A:16-27,A:121-232; A:28-120,A:233A-244 | THE OLIGOMERIC STRUCTURE OF HUMAN GRANZYME A REVEALS THE MOLECULAR DETERMINANTS OF SUBSTRATE SPECIFICITY |
1OWD | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OWE | A:13-131,A:249-258; A:1-12,A:132-248 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OWH | A:13-131,A:249-258; A:1-12,A:132-248 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OWI | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OWJ | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OWK | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1OYT | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR |
1P0S | H:16-27,H:121-232; H:28-120,H:233-245 | CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R |
1P57 | B:16-27,B:121-230; B:28-120,B:231-254 | EXTRACELLULAR DOMAIN OF HUMAN HEPSIN |
1P8V | C:13-117,C:245-257; C:1-12,C:118-244 | CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A |
1PJP | A:16-27,A:121-232; A:28-120,A:233-245 | THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE |
1PPB | H:28-120,H:233-247; H:16-27,H:121-232 | THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT |
1PPF | E:16-27,E:121-232; E:28-120,E:233-243 | X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR |
1Q3X | A:459-550,A:675-682; B:459-550,B:675-682; A:445-458,A:552-674; B:445-458,B:552-674 | CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2 |
1QBV | H:28-120,H:233-244; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR |
1QFK | H:153-164,H:261-381; H:165-260,H:382-395 | STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION |
1QHR | B:28-120,B:233-246; B:16-27,B:121-232 | NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS |
1QJ1 | B:28-120,B:233-246; B:16-27,B:121-232 | NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS |
1QJ6 | B:28-120,B:233-246; B:16-27,B:121-232 | NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS |
1QJ7 | B:28-120,B:233-246; B:16-27,B:121-232 | NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS |
1QRZ | A:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791 | CATALYTIC DOMAIN OF PLASMINOGEN |
1QUR | H:28-120,H:233-245; H:16-27,H:121-232 | HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR |
1RD3 | B:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-244 | 2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K |
1RFN | A:16-27,A:121-232; A:28-120,A:233-245 | HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE |
1RIW | C:185-286; B:37-183 | THROMBIN IN COMPLEX WITH NATURAL PRODUCT INHIBITOR OSCILLARIN |
1RJX | B:574-664,B:779-790; B:562-573,B:665-778 | HUMAN PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT |
1RRK | A:452-570; A:571-739 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B |
1RS0 | A:452-570; A:571-739 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP) |
1RTF | B:28-120,B:233-242; B:16-27,B:121-232 | COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA] |
1RTK | A:452-570; A:571-739 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID |
1SB1 | H:28-120,H:233-244; H:16-27,H:121-232 | NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4,5,6,7-TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS |
1SC8 | U:28-120,U:233-244; U:16-27,U:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX |
1SFQ | B:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245 | FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK |
1SG8 | B:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245 | CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN |
1SGI | B:28-120,B:233-243; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-243 | CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN |
1SHH | E:28-120,E:233-244; B:16-27,B:121-232; E:16-27,E:121-232; B:28-120,B:233-245 | SLOW FORM OF THROMBIN BOUND WITH PPACK |
1SHY | A:506-596,A:712-722; A:495-505,A:597-711 | THE CRYSTAL STRUCTURE OF HGF BETA-CHAIN IN COMPLEX WITH THE SEMA DOMAIN OF THE MET RECEPTOR. |
1SI5 | H:506-596,H:712-728; H:495-505,H:597-711 | PROTEASE-LIKE DOMAIN FROM 2-CHAIN HEPATOCYTE GROWTH FACTOR |
1SL3 | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1 HETEROCYCLE-ARYL BASED INHIBITOR |
1SPJ | A:28-120,A:233-245; A:16-27,A:121-232 | STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE |
1SQA | A:13-131,A:249-258; A:1-12,A:132-248 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1SQO | A:13-131,A:249-258; A:1-12,A:132-248 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1SQT | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE |
1SR5 | C:28-120,C:233-243; C:16-27,C:121-232 | ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE |
1T31 | A:16-27,A:121-232; A:28-120,A:233-245 | A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION |
1T32 | A:16-27,A:121-232; A:28-120,A:233-244 | A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION |
1T4U | H:49-153,H:275-287; H:37-48,H:154-274 | CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN |
1T4V | H:49-153,H:275-287; H:37-48,H:154-274 | CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN |
1TA2 | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1 |
1TA6 | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B |
1TB6 | H:28-120,H:233-245; H:16-27,H:121-232 | 2.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN-THROMBIN-HEPARIN TERNARY COMPLEX |
1TBZ | H:28-120,H:233-246; H:16-27,H:121-232 | HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN |
1THP | B:28-120,B:233-244; B:16-27,B:121-232 | STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
1THR | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR |
1THS | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR |
1TMB | H:28-120,H:233-246; H:16-27,H:121-232 | MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A |
1TMT | H:28-120,H:233-245; H:16-27,H:121-232 | CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS |
1TMU | H:28-120,H:233-245; H:16-27,H:121-232 | CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS |
1TOM | H:28-120,H:233-245; H:16-27,H:121-232 | ALPHA-THROMBIN COMPLEXED WITH HIRUGEN |
1TQ0 | B:28-120,B:233-243; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-243 | CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM |
1TQ7 | B:28-120,B:233-243; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK |
1TRN | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246 | CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151 |
1TWX | B:28-120,B:233-246; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE THROMBIN MUTANT D221A/D222K |
1U6Q | A:13-118,A:235-244; A:1-12,A:119-234 | SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE |
1UMA | H:28-120,H:233-246; H:16-27,H:121-232 | ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE |
1UVS | H:28-120,H:233-237; H:16-27,H:121-232 | BOVINE THROMBIN--BM51.1011 COMPLEX |
1V3X | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE |
1VJ9 | U:28-120,U:233-244; U:16-27,U:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX |
1VJA | U:28-120,U:233-244; U:16-27,U:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT463 COMPLEX |
1VR1 | H:28-120,H:233-241; H:16-27,H:121-232 | SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1 |
1VZQ | H:28-120,H:233-255; H:16-27,H:121-232 | COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165 |
1W0Y | H:16-27,H:121-232; H:28-120,H:233-246 | TF7A_3771 COMPLEX |
1W2K | H:16-27,H:121-232; H:28-120,H:233-246 | TF7A_4380 COMPLEX |
1W7G | H:28-120,H:233-247; H:16-27,H:121-232 | ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107 |
1W7X | H:16-27,H:121-232; H:28-120,H:233-246 | FACTOR7 - 413 COMPLEX |
1W8B | H:16-27,H:121-232; H:28-120,H:233-246 | FACTOR7 - 413 COMPLEX |
1WAY | B:28-120,B:233-246; B:16-27,B:121-232 | ACTIVE SITE THROMBIN INHIBITORS |
1WBG | B:28-120,B:233-246; B:16-27,B:121-232 | ACTIVE SITE THROMBIN INHIBITORS |
1WQV | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE |
1WSS | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4 |
1WTG | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE |
1WU1 | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE |
1WUN | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE |
1WV7 | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE |
1XKA | C:16-27,C:121-232; C:28-120,C:233-245 | FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID |
1XKB | C:16-27,C:121-232; C:28-120,C:233-245; D:28-120,D:233-244; D:16-27,D:121-232 | FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID |
1XM1 | A:28-120,A:233-245; A:16-27,A:121-232 | NONBASIC THROMBIN INHIBITOR COMPLEX |
1XMN | B:28-120,B:233-246; F:16-27,F:121-232; H:16-27,H:121-232; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-246; F:28-120,F:233-246; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN |
1XX9 | B:28-121,B:234-245; A:28-121,A:234-244; B:16-27,B:122-233; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R |
1XXD | A:28-121,A:234-245; B:28-121,B:234-245; A:16-27,A:122-233; B:16-27,B:122-233 | CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN |
1XXF | A:28-121,A:234-244; B:28-121,B:234-244; A:16-27,A:122-233; B:16-27,B:122-233 | CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP) |
1YBW | A:408-419,A:520-633; B:408-419,B:520-633; A:420-519,A:634-645; B:420-519,B:634-645 | PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR |
1YC0 | A:408-419,A:520-633; A:420-519,A:634-646 | SHORT FORM HGFA WITH FIRST KUNITZ DOMAIN FROM HAI-1 |
1YGC | H:16-27,H:121-232; H:28-120,H:233-246 | SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR |
1YPE | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN INHIBITOR COMPLEX |
1YPG | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN INHIBITOR COMPLEX |
1YPJ | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN INHIBITOR COMPLEX |
1YPK | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN INHIBITOR COMPLEX |
1YPL | H:28-120,H:233-244; H:16-27,H:121-232 | X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1008 |
1YPM | H:28-120,H:233-244; H:16-27,H:121-232 | X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1014 |
1Z6E | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389) |
1Z6J | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR |
1Z71 | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE |
1Z8G | A:163-174,A:276-392; A:175-275,A:393-417 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE TRANSMEMBRANE SERINE PROTEASE HEPSIN WITH COVALENTLY BOUND PREFERRED SUBSTRATE. |
1Z8I | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193A BOUND TO PPACK |
1Z8J | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193P BOUND TO PPACK |
1ZGI | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21 |
1ZGV | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2 |
1ZHM | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE COAGULATION FACTOR XIA IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K437 MUTANT) |
1ZHP | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K505 MUTANT) |
1ZHR | A:28-121,A:234-245; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-C482S-K437A MUTANT) |
1ZJD | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH KUNITZ PROTEASE INHIBITOR DOMAIN OF PROTEASE NEXIN II |
1ZLR | A:28-121,A:234-244; A:16-27,A:122-233 | FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH 2-GUANIDINO-1-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ETHYL NICOTINATE |
1ZMJ | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH 4-(GUANIDINOMETHYL)-PHENYLBORONIC ACID |
1ZML | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE |
1ZMN | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3, 2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE |
1ZOM | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR |
1ZPB | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE |
1ZPC | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-[2-(3-CHLORO-PHENYL)-2-HYDROXY-ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-3-METHYL-BUTYRAMIDE |
1ZPZ | A:28-121,A:234-244; A:16-27,A:122-233 | FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH N-((R)-1-(4-BROMOPHENYL)ETHYL)UREA-ASN-VAL-ARG-ALPHA-KETOTHIAZOLE |
1ZRB | A:28-120,A:233-244; A:16-27,A:121-232 | THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B |
1ZRK | A:28-121,A:234-244; A:16-27,A:122-233 | FACTOR XI COMPLEXED WITH 3-HYDROXYPROPYL 3-(7-AMIDINONAPHTHALENE-1-CARBOXAMIDO)BENZENESULFONATE |
1ZSJ | A:28-121,A:234-245; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE |
1ZSK | A:28-121,A:234-245; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER |
1ZSL | A:28-121,A:234-244; A:16-27,A:122-233 | FACTOR XI COMPLEXED WITH A PYRIMIDINONE INHIBITOR |
1ZTJ | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-BENZYLAMINO-2-METHYLSULFANYL-6-OXO-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE |
1ZTK | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-AMINO-6-OXO-2-M-TOLYL-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE |
1ZTL | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]-2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE |
2A0Q | B:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-244 | STRUCTURE OF THROMBIN IN 400 MM POTASSIUM CHLORIDE |
2A2Q | H:16-27,H:121-232; H:28-120,H:233-246 | COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+ |
2A2X | H:28-120,H:233-245; H:16-27,H:121-232 | ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN INH12 |
2A45 | B:28-120,B:233-246; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-246 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL "E" REGION OF FIBRIN |
2AEI | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID |
2AER | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX. |
2AFQ | D:28-120,D:233-244; D:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-246 | 1.9 ANGSTROM CRYSTAL STRUCTURE OF WILD-TYPE HUMAN THROMBIN IN THE SODIUM FREE STATE |
2ANK | H:28-120,H:233-245; H:16-27,H:121-232 | ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN AND AN EXOSITE DECAPEPTIDE |
2ANM | H:28-120,H:233-244; H:16-27,H:121-232 | TERNARY COMPLEX OF AN ORALLY ACTIVE THROMBIN INHIBITOR WITH HUMAN THROMBIN AND A C-TERMINAL HIRUDIN DERIVED EXO-SIT INHIBITOR |
2ANW | A:28-120,A:234-245; A:16-27,A:121-233 | EXPRESSION, CRYSTALLIZATION AND THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS |
2ANY | A:28-120,A:234-245; A:16-27,A:121-233 | EXPRESSION, CRYSTALLIZATION AND THE THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS |
2ASU | B:484-492,B:587-699; B:493-586,B:700-708 | CRYSTAL STRUCTURE OF THE BETA-CHAIN OF HGFL/MSP |
2B5T | B:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245 | 2.1 ANGSTROM STRUCTURE OF A NONPRODUCTIVE COMPLEX BETWEEN ANTITHROMBIN, SYNTHETIC HEPARIN MIMETIC SR123781 AND TWO S195A THROMBIN MOLECULES |
2B7D | H:16-27,H:121-232; H:28-120,H:233-246 | FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL |
2B8O | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX |
2BDG | A:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-244; B:28-120,B:235-244 | HUMAN KALLIKREIN 4 COMPLEX WITH NICKEL AND P-AMINOBENZAMIDINE |
2BDH | A:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244 | HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE |
2BDI | A:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; E:16-27,E:121-234; F:16-27,F:121-234; G:16-27,G:121-234; H:16-27,H:121-234; I:16-27,I:121-234; J:16-27,J:121-234; K:16-27,K:121-234; L:16-27,L:121-234; M:16-27,M:121-234; N:16-27,N:121-234; O:16-27,O:121-234; P:16-27,P:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244; E:28-120,E:235-244; F:28-120,F:235-244; G:28-120,G:235-244; H:28-120,H:235-244; I:28-120,I:235-244; J:28-120,J:235-244; K:28-120,K:235-244; L:28-120,L:235-244; M:28-120,M:235-244; N:28-120,N:235-244; O:28-120,O:235-244; P:28-120,P:235-244 | HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P-AMINOBENZAMIDINE |
2BDY | A:49-153,A:275-286; A:37-48,A:154-274 | THROMBIN IN COMPLEX WITH INHIBITOR |
2BM2 | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE |
2BMG | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 |
2BOH | B:16-27,B:121-232; B:28-120,B:233-245 | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND "1" |
2BOK | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA - CATION |
2BQ6 | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 |
2BQ7 | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 |
2BQW | B:16-27,B:121-232; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 |
2BVR | H:28-120,H:233-243; H:16-27,H:121-232 | HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET |
2BZ6 | H:16-27,H:121-232; H:28-120,H:233-246 | ORALLY AVAILABLE FACTOR7A INHIBITOR |
2C8W | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2C8X | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2C8Y | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2C8Z | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2C90 | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2C93 | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN INHIBITORS |
2CF8 | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR |
2CF9 | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR |
2CJI | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2CN0 | H:28-120,H:233-244; H:16-27,H:121-232 | COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED INHIBITOR |
2D1J | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5-CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[3,2-B]PYRIDINE N-OXIDE |
2D26 | C:28-120,C:233-245; C:20-27,C:121-232 | ACTIVE SITE DISTORTION IS SUFFICIENT FOR PROTEINASE INHIBIT SECOND CRYSTAL STRUCTURE OF COVALENT SERPIN-PROTEINASE COMPLEX |
2EC9 | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607 |
2EI6 | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
2EI7 | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
2EI8 | A:16-27,A:121-232; A:28-120,A:233-243 | FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-4-(N,N-DIMETHYLCARBAMOYL)-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL) CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
2F9B | H:16-27,H:121-232; H:28-120,H:233-246 | DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS |
2F9N | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN |
2F9O | C:28-120,C:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; D:28-120,D:233-244; A:28-120,A:233-243; B:28-120,B:233-243 | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G |
2F9P | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-243 | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN |
2FDA | A:28-121,A:234-244; A:16-27,A:122-233 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COAGULATION FACTOR XIA IN COMPLEX WITH ALPHA-KETOTHIAZOLE ARGININE DERIVED LIGAND |
2FEQ | H:28-120,H:233-245; H:16-27,H:121-232 | ORALLY ACTIVE THROMBIN INHIBITORS |
2FES | H:28-120,H:233-245; H:16-27,H:121-232 | ORALLY ACTIVE THROMBIN INHIBITORS |
2FIR | H:16-27,H:121-232; H:28-120,H:233-246 | CRYSTAL STRUCTURE OF DFPR-VIIA/STF |
2FLB | H:16-27,H:121-232; H:28-120,H:233-246 | DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR |
2FLR | H:16-27,H:121-232; H:28-120,H:233-246 | NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS |
2FPZ | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE |
2FS8 | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382 |
2FS9 | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427 |
2FWW | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME |
2FXR | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382 |
2FZZ | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE |
2G00 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE |
2GD4 | B:16-27,B:121-232; H:16-27,H:121-232; B:28-120,B:233-249; H:28-120,H:233-244 | CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX |
2GDD | A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244 | HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592 |
2GDE | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN IN COMPLEX WITH INHIBITOR |
2GP9 | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF-INHIBITED CONFORMATION |
2GV6 | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF MATRIPTASE WITH INHIBITOR CJ-730 |
2GV7 | A:28-120,A:233-244; A:16-27,A:121-232 | STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR CJ-672 |
2H9E | H:16-27,H:121-232; H:28-120,H:233-243 | CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX |
2H9T | H:28-120,H:233-246; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN IN COMPLEX WITH SURAMIN |
2HGT | H:28-120,H:233-246; H:16-27,H:121-232 | STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN |
2HNT | F:152-244; C:16-72; E:80-142 | CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN |
2HPP | H:28-120,H:233-245; H:16-27,H:121-232 | STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN |
2HPQ | H:28-120,H:233-245; H:16-27,H:121-232 | STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN |
2HVX | A:16-27,A:121-232; A:28-120,A:233-245 | DISCOVERY OF POTENT, ORALLY ACTIVE, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL CHYMASE BY USING STRUCTURE-BASED DRUG DESIGN |
2HWL | B:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH FIBRINOGEN GAMMA' PEPTIDE |
2J2U | A:16-27,A:121-232; A:28-120,A:233-243 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2J34 | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2J38 | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2J4I | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2J94 | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2J95 | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
2JH0 | D:28-120,D:233-246; D:16-27,D:121-232 | HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX |
2JH5 | D:28-120,D:233-246; D:16-27,D:121-232 | HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX |
2JH6 | D:28-120,D:233-246; D:16-27,D:121-232 | HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX |
2JKH | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA - CATION INHIBITOR COMPLEX |
2NWN | A:28-120,A:233-243; A:16-27,A:121-232 | NEW PHARMACOPHORE FOR SERINE PROTEASE INHIBITION REVEALED BY CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR COMPLEXED WITH A CYCLIC PEPTIDYL INHIBITOR, UPAIN-1 |
2O8T | A:28-120,A:233-242; A:16-27,A:121-232 | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS |
2O8U | A:28-120,A:233-242; A:16-27,A:121-232 | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS |
2O8W | A:28-120,A:233-242; A:16-27,A:121-232 | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS |
2OD3 | B:28-120,B:233-244; B:16-27,B:121-232 | HUMAN THROMBIN CHIMERA WITH HUMAN RESIDUES 184A, 186, 186A, 186B, 186C AND 222 REPLACED BY MURINE THROMBIN EQUIVALENTS. |
2OQ5 | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF DESC1, A NEW MEMBER OF THE TYPE II TRANSMEMBRANE SERINE PROTEINASES FAMILY |
2P16 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE |
2P3F | H:16-27,H:121-232; H:28-120,H:233-245 | CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX |
2P3T | B:16-27,B:121-232; B:28-120,B:233-243 | CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE |
2P3U | B:16-27,B:121-232; B:28-120,B:233-243 | CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663} |
2P93 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE |
2P94 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE |
2P95 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE |
2PGB | B:28-120,B:233-245; B:16-27,B:121-232 | INHIBITOR-FREE HUMAN THROMBIN MUTANT C191A-C220A |
2PGQ | B:28-120,B:233-245; B:16-27,B:121-232 | HUMAN THROMBIN MUTANT C191A-C220A IN COMPLEX WITH THE INHIBITOR PPACK |
2PHB | A:16-27,A:121-232; A:28-120,A:233-244 | AN ORALLY EFFICACIOUS FACTOR XA INHIBITOR |
2PKS | C:185-286; B:37-183 | THROMBIN IN COMPLEX WITH INHIBITOR |
2PR3 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA INHIBITOR |
2PSX | A:16-27,A:121-234; A:28-120,A:235-246 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN |
2PSY | A:16-27,A:121-234; A:28-120,A:235-246 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN AND ZINC |
2PUQ | H:153-164,H:261-381; H:165-260,H:382-395 | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
2PW8 | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF SULFO-HIRUDIN COMPLEXED TO THROMBIN |
2Q1J | A:16-27,A:121-232; A:28-120,A:233-244 | THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS |
2QXG | A:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-246; B:28-120,B:235-246 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA-ALA-PHE-CHLOROMETHYLKETONE |
2QXH | A:16-27,A:121-234; A:28-120,A:235-246 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE |
2QXI | A:16-27,A:121-234; A:28-120,A:235-246 | HIGH RESOLUTION STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE |
2QXJ | A:16-27,A:121-234; A:28-120,A:235-246 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE AND COPPER |
2QY0 | B:447-458,B:559-674; D:447-458,D:559-674; D:459-558,D:675-686; B:459-558,B:675-686 | ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS |
2R0K | A:16-27,A:121-230; A:28-120,A:231-243 | PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58 |
2R2M | B:49-153,B:275-287; B:37-48,B:154-274 | 2-(2-CHLORO-6-FLUOROPHENYL)ACETAMIDES AS POTENT THROMBIN INHIBITORS |
2R2W | U:28-120,U:233-244; U:16-27,U:121-232 | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-GPPE COMPLEX |
2R9P | A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245 | HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI) |
2RA0 | A:16-27,A:121-232; A:28-120,A:233-244 | X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE |
2RA3 | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246 | HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) |
2RG3 | A:16-27,A:121-232; A:28-120,A:233-243 | COVALENT COMPLEX STRUCTURE OF ELASTASE |
2THF | B:28-120,B:233-244; B:16-27,B:121-232 | STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
2UUF | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION |
2UUJ | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN-HIRUGEN-GW473178 TERNARY COMPLEX AT 1.32A RESOLUTION |
2UUK | B:28-120,B:233-246; B:16-27,B:121-232 | THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION |
2UWL | A:16-27,A:121-232; A:28-120,A:233-244 | SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA |
2UWO | A:16-27,A:121-232; A:28-120,A:233-244 | SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA |
2UWP | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA INHIBITOR COMPLEX |
2V3H | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN WITH 3-CYCLE NO F |
2V3O | H:28-120,H:233-244; H:16-27,H:121-232 | THROMBIN WITH 3-CYCLE WITH F |
2VH0 | A:16-27,A:121-232; A:28-120,A:233-244 | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS |
2VH6 | A:16-27,A:121-232; A:28-120,A:233-244 | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS |
2VIN | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VIO | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VIP | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VIQ | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VIV | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VIW | A:28-120,A:233-245; A:16-27,A:121-232 | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
2VNT | A:22-128,A:245-254; A:10-21,A:129-244; B:10-21,B:129-244; D:10-21,D:129-244; E:10-21,E:129-244; C:8-21,C:129-244; F:8-21,F:129-244; B:22-128,B:245-254; C:22-128,C:245-254; D:22-128,D:245-254; E:22-128,E:245-254; F:22-128,F:245-254 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE |
2VVC | A:16-27,A:121-232; A:28-120,A:233-243; B:28-120,B:233-243; B:16-27,B:121-232 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2VVU | A:16-27,A:121-232; A:28-120,A:233-244 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2VVV | A:16-27,A:121-232; A:28-120,A:233-244 | AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR |
2VWL | A:16-27,A:121-232; A:28-120,A:233-245 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2VWM | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2VWN | A:16-27,A:121-232; A:28-120,A:233-245 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2VWO | A:16-27,A:121-232; A:28-120,A:233-245 | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
2W26 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH BAY59-7939 |
2W3I | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2 |
2W3K | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1 |
2WPH | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE TRIPLE MUTANT |
2WPI | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE DOUBLE MUTANT |
2WPJ | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED |
2WPK | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED |
2WPL | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED |
2WPM | S:16-27,S:121-232; S:28-120,S:233-245 | FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED |
2WUB | C:16-27,C:121-230; A:16-27,A:121-230; A:28-120,A:231-244; C:28-120,C:231-244 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP |
2WUC | A:16-27,A:121-230; A:28-120,A:231-244 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE |
2XBV | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XBW | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XBX | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XBY | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XC0 | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XC4 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2XC5 | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
2Z7F | E:16-27,E:121-232; E:28-120,E:233-243 | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN NEUTROPHIL ELASTASE WITH 1/2SLPI |
2ZA5 | A:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258 | CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR |
2ZC9 | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN IN COMPLEX WITH INHIBITOR |
2ZCH | P:28-120,P:233-245; P:16-27,P:121-232 | CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY |
2ZCK | P:28-120,P:234-246; P:16-27,P:121-233 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY |
2ZCL | P:28-120,P:233-245; P:16-27,P:121-232 | CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY |
2ZDA | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S1 POCKET |
2ZDV | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S1 POCKET |
2ZEB | A:13-109,A:232-243; A:1-12,A:110-231; B:1-12,B:110-231; C:1-12,C:110-231; D:1-12,D:110-231; B:13-109,B:232-243; C:13-109,C:232-243; D:13-109,D:232-243 | POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE |
2ZEC | A:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258 | POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE |
2ZF0 | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S1 POCKET |
2ZFF | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S1-POCKET |
2ZFP | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INIBITION |
2ZFQ | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZFR | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZG0 | H:28-120,H:233-245; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZGB | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZGC | A:13-104,A:219-231; A:1-12,A:105-218 | CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME M |
2ZGH | A:13-104,A:219-231; A:1-12,A:105-218 | CRYSTAL STRUCTURE OF ACTIVE GRANZYME M BOUND TO ITS PRODUCT |
2ZGJ | A:13-104,A:219-231; A:1-12,A:105-218 | CRYSTAL STRUCTURE OF D86N-GZMM COMPLEXED WITH ITS OPTIMAL SYNTHESIZED SUBSTRATE |
2ZGX | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZHE | H:28-120,H:233-246; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZHF | H:28-120,H:233-245; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZHQ | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZHW | H:28-120,H:233-245; H:16-27,H:121-232 | EXPLORING THROMBIN S3 POCKET |
2ZI2 | H:28-120,H:233-245; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZIQ | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZKS | A:13-104,A:219-231; A:1-12,A:105-218 | STRUCTURAL INSIGHTS INTO THE PROTEOLYTIC MACHINERY OF APOPTOSIS-INDUCING GRANZYME M |
2ZNK | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
2ZO3 | H:28-120,H:233-246; H:16-27,H:121-232 | BISPHENYLIC THROMBIN INHIBITORS |
2ZP0 | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE |
2ZWL | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR |
2ZZU | H:16-27,H:121-232; H:28-120,H:233-246 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE |
3B9F | H:28-120,H:233-245; H:16-27,H:121-232 | 1.6 A STRUCTURE OF THE PCI-THROMBIN-HEPARIN COMPLEX |
3BEF | B:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245 | CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE EXTRACELLULAR FRAGMENT OF PAR1 |
3BEI | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF_INHIBITED CONFORMATION |
3BF6 | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN:SURAMIN COMPLEX |
3BG8 | A:382-480,A:596-607; A:370-381,A:481-595 | CRYSTAL STRUCTURE OF FACTOR XIA IN COMPLEX WITH CLAVATADINE A |
3BIU | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN THROMBIN-IN COMPLEX WITH UB-THR10 |
3BIV | H:28-120,H:233-244; H:16-27,H:121-232 | HUMAN THROMBIN-IN COMPLEX WITH UB-THR11 |
3BN9 | A:28-120,A:233-244; B:28-120,B:233-244; A:16-27,A:121-232; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2 |
3BSQ | B:16-27,B:117-227; A:16-27,A:117-227; C:16-27,C:117-227; A:28-116,A:228-238; C:28-116,C:228-238; B:28-116,B:228-237 | CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI |
3C1K | A:28-120,A:233-244; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR 15 |
3C27 | B:49-153,B:275-287; B:37-48,B:154-274 | CYANOFLUOROPHENYLACETAMIDES AS ORALLY EFFICACIOUS THROMBIN INHIBITORS |
3CEN | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE |
3CS7 | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
3D49 | H:28-120,H:233-245; H:16-27,H:121-232 | THROMBIN INHIBITION |
3DA9 | B:49-153,B:275-288; B:37-48,B:154-274 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR |
3DD2 | H:28-120,H:233-245; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF AN RNA APTAMER BOUND TO HUMAN THROMBIN |
3DHK | H:28-120,H:233-246; H:16-27,H:121-232 | BISPHENYLIC THROMBIN INHIBITORS |
3DT0 | H:28-120,H:233-246; H:16-27,H:121-232 | UNDERSTANDING THROMBIN INHIBITION |
3DUX | H:28-120,H:233-246; H:16-27,H:121-232 | UNDERSTANDING THROMBIN INHIBITION |
3E0N | B:28-120,B:233-252; B:16-27,B:121-232 | THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH DFFR-CHLOROMETHYL KETONE INHIBITOR |
3E0P | B:28-120,B:233-247; B:16-27,B:121-232 | THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH A COVALENT BENZOXAZOLE INHIBITOR |
3E16 | B:28-120,B:233-248; B:16-27,B:121-232 | X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH BENZOXAZOLE WARHEAD PEPTIDOMIMIC, LYSINE IN P3 |
3E1X | B:28-120,B:233-248; B:16-27,B:121-232 | THE CRYSTAL STRUCTURE OF APO PROSTASIN AT 1.7 ANGSTROMS RESOLUTION |
3EE0 | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF HUMAN THROMBIN (SPACE GROUP P2(1)2(1)2(1)) |
3EGK | H:28-120,H:233-246; H:16-27,H:121-232 | KNOBLE INHIBITOR |
3ELA | H:153-164,H:261-381; H:165-260,H:382-395 | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
3ENS | B:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248; D:16-27,D:121-232 | CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE |
3EQ0 | H:28-120,H:233-243; H:16-27,H:121-232 | THROMBIN INHIBITOR |
3F68 | H:28-120,H:233-246; H:16-27,H:121-232 | THROMBIN INHIBITION |
3FFG | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
3FVF | B:28-120,B:233-249; B:16-27,B:121-232 | THE CRYSTAL STRUCTURE OF PROSTASIN COMPLEXED WITH CAMOSTAT AT 1.6 ANGSTROMS RESOLUTION |
3GIC | B:28-120,B:233-243; B:16-27,B:121-232 | STRUCTURE OF THROMBIN MUTANT DELTA(146-149E) IN THE FREE FORM |
3GIS | F:28-120,F:233-244; F:16-27,F:121-232; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-245; D:28-120,D:233-245 | CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN |
3GOV | B:461-570,B:687-699; B:449-460,B:571-686 | CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-1 |
3GYL | B:28-120,B:233-248; B:16-27,B:121-232 | STRUCTURE OF PROSTASIN AT 1.3 ANGSTROMS RESOLUTION IN COMPLEX WITH A CALCIUM ION. |
3GYM | A:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242 | STRUCTURE OF PROSTASIN IN COMPLEX WITH APROTININ |
3HAT | H:28-120,H:233-246; H:16-27,H:121-232 | ACTIVE SITE MIMETIC INHIBITION OF THROMBIN |
3HKJ | E:28-120,E:233-246; E:16-27,E:121-232; B:16-27,B:121-232; B:28-120,B:233-247 | CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1 |
3HPT | D:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248 | CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE |
3IG6 | D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-242 | LOW MOLECULAR WEIGTH HUMAN UROKINASE TYPE PLASMINOGEN ACTIVATOR 2-[6-(3'-AMINOMETHYL-BIPHENYL-3-YLOXY)-4-(3-DIMETHYLAMINO-PYRROLIDIN-1-YL)-3,5-DIFLUORO-PYRIDIN-2-YLOXY]-4-DIMETHYLAMINO-BENZOIC ACID COMPLEX |
3JZ1 | B:28-120,B:233-246; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E:NA+ FORM |
3JZ2 | B:28-120,B:233-245; B:16-27,B:121-232 | CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E* FORM |
3K2U | A:16-27,A:121-230; A:28-120,A:231-243 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40 |
3K9X | B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-248; D:28-120,D:233-248 | X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE |
3KCG | H:16-27,H:121-232; H:28-120,H:233-245 | CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA-PENTASACCHARIDE COMPLEX |
3KGP | A:28-120,A:233-242; A:16-27,A:121-232 | CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL |
3KHV | A:28-120,A:233-243; A:16-27,A:121-232 | CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL |
3KID | U:28-120,U:233-243; U:16-27,U:121-232 | THE CRYSTAL STRUCTURES OF 2-AMINOBENZOTHIAZOLE-BASED INHIBITORS IN COMPLEXES WITH UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
3KL6 | A:16-27,A:121-232; A:28-120,A:233-242 | DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT, SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR |
3KQB | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE |
3KQC | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
3KQD | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
3KQE | A:16-27,A:121-232; A:28-120,A:233-244 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
3LC3 | A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245 | BENZOTHIOPHENE INHIBITORS OF FACTOR IXA |
3LC5 | A:16-27,A:121-232; A:28-120,A:233-245 | SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA |
4HTC | H:28-120,H:233-245; H:16-27,H:121-232 | THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX |
4THN | H:28-120,H:233-246; H:16-27,H:121-232 | THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE. |
5GDS | H:28-120,H:233-246; H:16-27,H:121-232 | HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX |
7KME | H:28-120,H:233-246; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711. |
8KME | 2:28-120,2:233-244; 2:16-27,2:121-232 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770. |